EVTA Stock Chart & Stats
€1.54
€0.02(1.28%)
At close: 4:00 PM EDT
€1.54
€0.02(1.28%)
Day’s Range― - ―
52-Week Range€1.33 - €3.54
Previous CloseN/A
Volume0.00
Average Volume (3M)535.00
Market Cap
€561.76M
Enterprise Value€1.01K
Total Cash (Recent Filing)€465.59M
Total Debt (Recent Filing)€475.87M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding355,819,120
10 Day Avg. Volume392
30 Day Avg. Volume535
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.41Price Target Upside56.57% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)€595.83M
Bulls Say, Bears Say
Bulls Say
Integrated Discovery Platform And PartnershipsEvotec’s integrated scientific platforms, proprietary libraries and AI-enabled capabilities support repeatable collaboration with biotech and pharma partners, strengthening its role as a development partner and creating potential milestone and royalty opportunities.
Underlying Biologics Services MomentumUnderlying growth in biologics services indicates customer demand remains healthier than reported figures suggest. This supports longer-term utilization and revenue potential as one-off licensing effects fade and the platform expands.
Transformation And Liquidity SupportThe Horizon program can improve cost discipline, site utilization and scalability over the next two years, while net cash and substantial liquidity provide funding capacity to execute the restructuring and sustain strategic programs.
Bears Say
Persistent Revenue And Profitability WeaknessRevenue contraction and materially weaker margins show that Evotec is not currently converting its scientific infrastructure into consistent operating leverage. Persistent losses could restrict reinvestment and weaken financial flexibility if recovery is delayed.
Negative Cash GenerationNegative operating and free cash flow increase reliance on existing liquidity, asset monetization or external financing. Unless cash conversion improves sustainably, Evotec may have less capacity to fund growth, absorb volatility or pursue platform investments.
Market Softness And Lowered OutlookThe guidance reduction and weak first-half conversion signal that biotech funding pressure and soft discovery demand are affecting near-term contract realization. This raises execution risk for the transformation and delays a return to profitability.
Evotec AG News
EVTA FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was €1.33 and its highest was €3.54 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is €561.76M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Nov 05, 2026 which is in 56 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Aug 13, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of -€0.035 by -€0.095.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.23.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,120 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -€0.13 in its last earnings report, missing expectations of -€0.035. Following the earnings report the stock price went down -7.447%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in DE:EVTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.41 (56.57% Upside)
€2.41 (56.57% Upside)
Blogger Sentiment
Bullish
DE:EVTA Sentiment 67%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVTA Company Deck
EVTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: near-term financials were weak with material revenue declines (H1 revenues down ~19%) and negative adjusted EBITDA (H1 EUR -42.7m), and management revised full-year 2026 guidance downward due mainly to timing shifts in strategic partnership milestone recognition. Offsetting these weaknesses are encouraging commercial leading indicators (inbound inquiries +~30%, proposals >45%, base D&PD net sales +~28% in H1), a healthy pipeline of 10–20 strategic partnership opportunities, strong liquidity (EUR 465.6m), active cost-savings via the Horizon program (~EUR 75m run-rate by 2027), and recent senior hires to improve commercial conversion. Overall, the issues appear driven largely by timing and phasing rather than loss of pipeline quality, but 2026 results and guidance remain meaningfully impacted.View all DE:EVTA earnings summariesEVTA Stock 12 Month Forecast
Average Price Target
€2.41
▲(56.57% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―